A Phase 1 interventional study of 5 mg empagliflozin/850 mg metformin FDC and 12.5 mg empagliflozin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-24.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of Empagliflozin and metformin compared to the administration of single tablets (Empagliflozin and metformin ) in Chinese subjects. The availability of a fixed dose combination tablet is expected to significantly enhance patient's compliance with antidiabetic treatment, in particular with concern to the frequent polypharmacy in diabetic patients.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy male and female subjects
Exclusion criteria:
Any relevant deviation from healthy conditions
24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
Drug: 12.5 mg empagliflozin · Drug: 850 mg metformin · Drug: 12.5 mg empagliflozin/850 mg metformin FDC
24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
Drug: 5 mg empagliflozin/850 mg metformin FDC · Drug: 5 mg empagliflozin · Drug: 850 mg metformin
24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
Drug: 12.5 mg empagliflozin · Drug: 12.5 mg empagliflozin/500 mg metformin FDC · Drug: 500 mg metformin
24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order
Drug: 5 mg empagliflozin · Drug: 5 mg empagliflozin/500 mg metformin FDC · Drug: 500 mg metformin
Drug pages: Empagliflozin · Metformin
5 mg empagliflozin/850 mg metformin FDC
10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
850mg metformin tablet
5 mg empagliflozin
5 mg empagliflozin
850 mg metformin
Drug pages: Empagliflozin · Metformin
12.5 mg empagliflozin/850 mg metformin FDC
Drug pages: Empagliflozin · Metformin
12.5 mg empagliflozin/500 mg metformin FDC
Drug pages: Empagliflozin · Metformin
5 mg empagliflozin/500 mg metformin FDC
500 mg metformin
500 mg metformin
AUC(0-∞) for Empagliflozin
Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 extrapolated to infinity
Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
AUC(0-∞) for Metformin
Area under the concentration-time curve of the metformin in plasma over the time interval from 0 extrapolated to infinity
Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Cmax for Empagliflozin
Maximum measured concentration of the empagliflozin in plasma
Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Cmax for Metformin
Maximum measured concentration of the metformin in plasma
Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
AUC(0-tz) of Empagliflozin
Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 up to the last quantifiable data point
Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
AUC(0-tz) of Metformin
Area under the concentration-time curve of the metformin in plasma over the time interval from 0 up to the last quantifiable data point
Time frame: 1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
The study was performed as an open-label, randomised, single-dose, two-way crossover trial consisting of four trial parts. In each trial part the aim was to investigate the relative bioavailability of the Test treatment (T) and to compare it with the Reference treatment (R).
| Milestone | T1R1 | R1T1 | T2R2 | R2T2 | T3R3 | R3T3 | T4R4 | R4T4 |
|---|---|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Completed | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 extrapolated to infinity
| nmol * h/L | T1 (FDC) | R1 (FC) | T2 (FDC) | R2 (FC) | T3 (FDC) | R3 (FC) | T4 (FDC) | R4 (FC) |
|---|---|---|---|---|---|---|---|---|
| AUC(0-∞) for Empagliflozin | 4330 ± 16.6 | 4110 ± 15.3 | 1680 ± 22.0 | 1630 ± 21.1 | 4200 ± 20.3 | 4060 ± 18.6 | 1610 ± 16.5 | 1560 ± 17.7 |
Area under the concentration-time curve of the metformin in plasma over the time interval from 0 extrapolated to infinity
| ng * h/mL | T1 (FDC) | R1 (FC) | T2 (FDC) | R2 (FC) | T3 (FDC) | R3 (FC) | T4 (FDC) | R4 (FC) |
|---|---|---|---|---|---|---|---|---|
| AUC(0-∞) for Metformin | 11600 ± 18.9 | 11100 ± 17.4 | 11700 ± 21.8 | 11000 ± 24.0 | 7800 ± 18.9 | 7510 ± 17.8 | 7030 ± 20.7 | 7340 ± 18.8 |
Maximum measured concentration of the empagliflozin in plasma
| nmol/L | T1 (FDC) | R1 (FC) | T2 (FDC) | R2 (FC) | T3 (FDC) | R3 (FC) | T4 (FDC) | R4 (FC) |
|---|---|---|---|---|---|---|---|---|
| Cmax for Empagliflozin | 644 ± 18.2 | 605 ± 15.3 | 263 ± 17.7 | 237 ± 20.7 | 569 ± 22.1 | 561 ± 25.3 | 228 ± 16.4 | 221 ± 22.2 |
Maximum measured concentration of the metformin in plasma
| ng/mL | T1 (FDC) | R1 (FC) | T2 (FDC) | R2 (FC) | T3 (FDC) | R3 (FC) | T4 (FDC) | R4 (FC) |
|---|---|---|---|---|---|---|---|---|
| Cmax for Metformin | 1920 ± 20.9 | 1830 ± 16.6 | 1950 ± 26.4 | 1840 ± 26.0 | 1290 ± 22.2 | 1230 ± 27.1 | 1150 ± 25.5 | 1190 ± 21.3 |
Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 up to the last quantifiable data point
| nmol * h/L | T1 (FDC) | R1 (FC) | T2 (FDC) | R2 (FC) | T3 (FDC) | R3 (FC) | T4 (FDC) | R4 (FC) |
|---|---|---|---|---|---|---|---|---|
| AUC(0-tz) of Empagliflozin | 4270 ± 16.6 | 4060 ± 14.7 | 1650 ± 21.5 | 1600 ± 21.0 | 4140 ± 19.7 | 4010 ± 18.5 | 1580 ± 16.7 | 1540 ± 17.7 |
Area under the concentration-time curve of the metformin in plasma over the time interval from 0 up to the last quantifiable data point
| ng* h/mL | T1 (FDC) | R1 (FC) | T2 (FDC) | R2 (FC) | T3 (FDC) | R3 (FC) | T4 (FDC) | R4 (FC) |
|---|---|---|---|---|---|---|---|---|
| AUC(0-tz) of Metformin | 11400 ± 19.2 | 10800 ± 17.6 | 11400 ± 23.1 | 10800 ± 25.1 | 7630 ± 18.9 | 7420 ± 17.9 | 6790 ± 24.7 | 7230 ± 18.3 |
Collected over First drug administration until 7 days after last drug administration, up to 8 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T1 (FDC) | — | 0/24 (0%) | 8/24 (33.3%) |
| R1 (FC) | — | 0/24 (0%) | 8/24 (33.3%) |
| T2 (FDC) | — | 0/24 (0%) | 9/24 (37.5%) |
| R2 (FC) | — | 0/24 (0%) | 11/24 (45.8%) |
| T3 (FDC) | — | 0/24 (0%) | 12/24 (50%) |
| R3 (FC) | — | 0/24 (0%) | 11/24 (45.8%) |
| T4 (FDC) | — | 0/24 (0%) | 7/24 (29.2%) |
| R4 (FC) | — | 0/24 (0%) | 9/24 (37.5%) |
| Event | T1 (FDC) | R1 (FC) | T2 (FDC) | R2 (FC) | T3 (FDC) | R3 (FC) | T4 (FDC) | R4 (FC) |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/24 | 4/24 | 7/24 | 11/24 | 10/24 | 8/24 | 3/24 | 5/24 |
| NauseaGastrointestinal disorders | 1/24 | 2/24 | 2/24 | 0/24 | 1/24 | 1/24 | 3/24 | 1/24 |
| Bilirubin conjugated increasedInvestigations | 0/24 | 0/24 | 0/24 | 0/24 | 1/24 | 1/24 | 2/24 | 3/24 |
| Blood bilirubin increasedInvestigations | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 1/24 | 2/24 | 3/24 |
| Glucose urine presentInvestigations | 3/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 |
| Abdominal pain upperGastrointestinal disorders | 1/24 | 2/24 | 1/24 | 0/24 | 1/24 | 2/24 | 2/24 | 2/24 |
| VomitingGastrointestinal disorders | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 1/24 | 2/24 |
| Blood bilirubin unconjugated increasedInvestigations | 0/24 | 1/24 | 0/24 | 0/24 | 0/24 | 1/24 | 1/24 | 2/24 |
| DizzinessNervous system disorders | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/24 | 2/24 | 0/24 |
Treated set (TS): The TS included all subjects who were dispensed study medication and were documented to have received at least 1 dose of trial medication
| Age, Continuous(years) | T1R1 | R1T1 | T2R2 | R2T2 | T3R3 | R3T3 | T4R4 | R4T4 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 26.9 ± 4.8 | 27.0 ± 5.3 | 26.8 ± 5.3 | 24.3 ± 3.4 | 24.8 ± 4.3 | 24.4 ± 3.9 | 24.6 ± 3.7 | 25.6 ± 4.8 | 25.5 ± 4.5 |
| Sex: Female, Male(Participants) | T1R1 | R1T1 | T2R2 | R2T2 | T3R3 | R3T3 | T4R4 | R4T4 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 7 | 5 | 7 | 5 | 5 | 7 | 5 | 7 | 48 |
| Male | 5 | 7 | 5 | 7 | 7 | 5 | 7 | 5 | 48 |
The record gives a start of May 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Metformin